-
J651882-5mg
JAK2/FLT3-IN-1 (C007B-363095)
Price: $913.26List Price: $1,014.73JAK2/FLT3-IN-1 is a potent and orally active dual JAK2/FLT3 inhibitor with IC 50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2 , FLT3 , JAK1 and JAK3 , respectively. JAK2/FLT3-IN-1 has anti-cancer activityIn VitroJAK2/FLT3-IN-1 (0.008-1 μM: for 2 -
J649081-10mg
JGB1741 (C007B-362995)
Price: $485.86List Price: $539.85JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC 50 of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC 50 >:100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis -
J649081-1mg
JGB1741 (C007B-362996)
Price: $119.25List Price: $132.50JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC 50 of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC 50 >:100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis -
J649081-25mg
JGB1741 (C007B-362997)
Price: $913.26List Price: $1,014.73JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC 50 of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC 50 >:100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis -
J649081-50mg
JGB1741 (C007B-362998)
Price: $1,460.55List Price: $1,622.84JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC 50 of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC 50 >:100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis -
J649081-5mg
JGB1741 (C007B-362999)
Price: $336.97List Price: $374.41JGB1741 (ILS-JGB-1741) is a potent and specific SIRT1 activity inhibitor with an IC 50 of ∼15 μM. JGB1741 is a weak SIRT2 and SIRT3 inhibitor with an all IC 50 >:100 μM. JGB1741 increases the acetylated p53 levels leading to p53-mediated apoptosis -
18494-1
JNJ-7706621-1 mg
Price: $163.05List Price: $181.17A dual inhibitor of Cdks and Aurora kinases inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC<sub>50</sub>s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, -
18494-10
JNJ-7706621-10 mg
Price: $887.96List Price: $986.62A dual inhibitor of Cdks and Aurora kinases inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC<sub>50</sub>s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, -
18494-5
JNJ-7706621-5 mg
Price: $470.22List Price: $522.47A dual inhibitor of Cdks and Aurora kinases inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC<sub>50</sub>s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, -
DWK73662-13-1000EA
KIMBLE(R) KIM-KAP(R) PUSH CAP POLYPROPYLENE RED 13 MM
Price: $319.17List Price: $354.63KIM-KAP polypropylene closures for culture tubes Autoclavable Color coded Legal Information KIM-KAP is a registered trademark of DWK LIFE SCIENCES LLC KIMBLE is a registered trademark of DWK Life Sciences -
-
SML1506-5MG
KY-05009 (C005B-312015)
Price: $307.43List Price: $341.59Biochem/physiol Actions KY-05009 is a Traf2- and Nck-interacting kinase (TNIK) inhibitor that inhibits the epithelial-to-mesenchymal transition (EMT) in cancer cells. KY-05009 is also known as (5-(4-methylbenzamido)-2-(phenylamino)